Enterodiol and Enterolactone Modulate the Immune Response by Acting on Nuclear Factor-κB (NF-κB) Signaling

被引:48
作者
Corsini, Emanuela [1 ]
Dell'Agli, Mario [2 ]
Facchi, Alessandra [1 ]
De Fabiani, Emma
Lucchi, Laura [1 ]
Boraso, Maria Serena [1 ]
Marinovich, Marina [1 ]
Galli, Corrado L. [1 ]
机构
[1] Univ Milan, Toxicol Lab, I-20133 Milan, Italy
[2] Univ Milan, Lab Pharmacognosy, I-20133 Milan, Italy
关键词
Lignans; inflammation; enterodiol; enterolactone; NF-kappa B; cytokine; proliferation; PLANT LIGNANS; FLAXSEED; SECOISOLARICIRESINOL; METABOLISM; TARGET;
D O I
10.1021/jf100471n
中图分类号
S [农业科学];
学科分类号
09 ;
摘要
Lignan-rich whole-grain cereals, beans, berries, and nuts show protective effects against a variety of chronic diseases, including cancer. Lignans are converted by intestinal microflora to enterolactone (EL) and its oxidation product enterodiol (ED). To investigate the immunomodulatory effect of EL and ED in human cells, peripheral blood lymphocytes were treated with increasing physiologically relevant concentrations of EL and ED (0-1000 mu M) and stimulated with lipopolysaccharide (LPS) and anti-CD3 plus anti-CD28 monoclonal antibodies. A dose-related inhibition of cell proliferation and cytokine production was observed, with EL being the most active. Molecular investigations in THP-1 cells showed that both EL and ED prevented inhibitory-kappa B (I-kappa B) degradation and nuclear factor-kappa B (NF-kappa B) activation, which in turn resulted in decreased tumor necrosis factor-alpha (TNF-alpha) production. EL and ED were also able to pass the intestinal barrier and modulate cytokine production. The findings of the present study reveal potential mechanisms that could explain some in vivo beneficial effects of lignans.
引用
收藏
页码:6678 / 6684
页数:7
相关论文
共 40 条
[1]   Phyto-oestrogens and Western diseases [J].
Adlercreutz, H ;
Mazur, W .
ANNALS OF MEDICINE, 1997, 29 (02) :95-120
[2]  
[Anonymous], 2012, Molecular Cloning: A Laboratory Manual
[3]  
Arts ICW, 2005, AM J CLIN NUTR, V81, p317S, DOI 10.1093/ajcn/81.1.317S
[4]   NF-κB in inflammatory bowel disease [J].
Atreya, I. ;
Atreya, R. ;
Neurath, M. F. .
JOURNAL OF INTERNAL MEDICINE, 2008, 263 (06) :591-596
[5]   The NF-κB pathway as a potential target for autoimmune disease therapy [J].
Bacher, S ;
Schmitz, ML .
CURRENT PHARMACEUTICAL DESIGN, 2004, 10 (23) :2827-2837
[6]   I-KAPPA-B - A SPECIFIC INHIBITOR OF THE NF-KAPPA-B TRANSCRIPTION FACTOR [J].
BAEUERLE, PA ;
BALTIMORE, D .
SCIENCE, 1988, 242 (4878) :540-546
[7]   CARMA1-mediated NF-κB and JNK activation in lymphocytes [J].
Blonska, Marzenna ;
Lin, Xin .
IMMUNOLOGICAL REVIEWS, 2009, 228 :199-211
[8]   PRODUCTION AND METABOLISM OF LIGNANS BY THE HUMAN FECAL FLORA [J].
BORRIELLO, SP ;
SETCHELL, KDR ;
AXELSON, M ;
LAWSON, AM .
JOURNAL OF APPLIED BACTERIOLOGY, 1985, 58 (01) :37-43
[9]  
Brostjan C, 1997, J IMMUNOL, V158, P3836
[10]   FLAXSEED - A POTENTIAL TREATMENT FOR LUPUS NEPHRITIS [J].
CLARK, WF ;
PARBTANI, A ;
HUFF, MW ;
SPANNER, E ;
DESALIS, H ;
CHINYEE, I ;
PHILBRICK, DJ ;
HOLUB, BJ .
KIDNEY INTERNATIONAL, 1995, 48 (02) :475-480